Navigation Links
American Pacific Reports Fiscal 2013 Results; Provides Outlook For Fiscal 2014
Date:12/12/2013

ffset by increases in operating expenses of approximately $2.7 million. The most significant components of the increase in operating expenses relate to incremental investments in product research and business development in the amount of approximately $1.1 million and retirement benefits related costs in the amount of approximately $0.6 million.For the Fiscal 2013 fourth quarter, Fine Chemicals segment revenues declined compared to the Fiscal 2012 fourth quarter due to inter-quarter timing of production, shipments and the corresponding revenue recognition.  Fine Chemicals segment Adjusted Operating Profit declined in the Fiscal 2013 fourth quarter when compared to the Fiscal 2012 fourth quarter.  The Fine Chemicals segment has achieved stable manufacturing performance in Fiscal 2013, with the gross margin percentage in the Fiscal 2013 fourth quarter being comparable with the three preceding quarters in Fiscal 2013.  However, the lower revenue volume in the Fiscal 2013 fourth quarter provided less gross profit in the period.  Accordingly, because general and administrative expenses are relatively fixed from quarter to quarter, the lower gross profit contribution resulted in the reduction in Fine Chemicals segment operating profit. 

Specialty Chemicals SegmentOur Specialty Chemicals segment revenues include the operating results from our perchlorate, sodium azide and Halotron product lines, with our perchlorate product lines comprising 89% and 88% of Specialty Chemicals segment revenues in Fiscal 2013 and Fiscal 2012, respectively. 

Year Ended September 30, 2013 Compared to Year Ended September 30, 2012

  • Revenues increased to $82.6 million from $68.5 million.
  • Operating income was $48.0 million compared to $34.9 million.
  • Segment EBITDA was $49.1 million compared to $36.3 million.
  • Quarter Ended September 30, 2013 Compared to Quarter Ended September 30, 2012

  • Revenues
    '/>"/>

  • SOURCE American Pacific Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

    Related medicine technology :

    1. American Academy of Family Physicians Foundation Launches Cities for Life
    2. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
    3. Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry
    4. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
    5. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
    6. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
    7. NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
    8. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
    9. Purdue Pharma L.P. To Present Analysis Of Butrans® (buprenorphine) Transdermal System CIII Clinical Data At American Pain Society Annual Meeting
    10. Percutaneous Tibial Nerve Stimulation Included in the American Urological Associations Overactive Bladder Clinical Treatment Guidelines
    11. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... , July 29, 2014 Today, Frost ... Frost & Sullivan Best Practices Award for Customer ... a cloud-based platform that connects digital health application ... as providers, pharmaceutical companies, prevention and wellness companies, ... Each year, Frost & Sullivan presents ...
    (Date:7/29/2014)...   , First patient begins treatment ... safety of MSB0010718C in patients with metastatic Merkel cell carcinoma ... cancer lacking effective treatments   MSB0010718C is also currently ... for the treatment of solid tumors that aims to recruit ... of Merck KGaA, Darmstadt, Germany , today ...
    (Date:7/28/2014)... (NASDAQ: LMNX ) today announced financial results ... and operating highlights include the following: , ... percent increase over the second quarter of 2013. ... 9 percent increase over the second quarter of 2013.  ... which included 148 LX systems, 96 MAGPIX systems, and ...
    Breaking Medicine Technology:Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 2Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5Luminex Corporation Reports Second Quarter 2014 results 2Luminex Corporation Reports Second Quarter 2014 results 3Luminex Corporation Reports Second Quarter 2014 results 4Luminex Corporation Reports Second Quarter 2014 results 5Luminex Corporation Reports Second Quarter 2014 results 6Luminex Corporation Reports Second Quarter 2014 results 7Luminex Corporation Reports Second Quarter 2014 results 8Luminex Corporation Reports Second Quarter 2014 results 9Luminex Corporation Reports Second Quarter 2014 results 10Luminex Corporation Reports Second Quarter 2014 results 11Luminex Corporation Reports Second Quarter 2014 results 12Luminex Corporation Reports Second Quarter 2014 results 13Luminex Corporation Reports Second Quarter 2014 results 14Luminex Corporation Reports Second Quarter 2014 results 15Luminex Corporation Reports Second Quarter 2014 results 16Luminex Corporation Reports Second Quarter 2014 results 17
    ... Reportlinker.com announces that a new market research ... Cancer Pain Therapeutics - ... http://www.reportlinker.com/p0546769/Cancer-Pain-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... Assessment and Market Forecasts to 2017 ...
    ... YORK, June 1, 2011 ... market research report is available ... Interventional Neurology - ... and Market Forecasts to 2017 ...
    Cached Medicine Technology:Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 9Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 10Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 4Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 5Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 6Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 7Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 8Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 9Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 10Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 11Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 12
    (Date:7/29/2014)... HealthDay Reporter , MONDAY, July 28, 2014 (HealthDay ... may be able to take hormone replacement therapy soon after ... to a new study. Previous studies, including the large-scale ... effects on the heart. But, many of those women were ... past menopause. In this new study, researchers wanted ...
    (Date:7/29/2014)... Kelly and Zhi Sheng , assistant professors ... recently received a grant from the Commonwealth Health ... effort that may lead to new treatment approaches. , ... , The grant will fund a two-year project to ... the BRCA1 gene. This type of cancer often has ...
    (Date:7/29/2014)... (PRWEB) July 29, 2014 The global ... 9,542.3 million by 2020, growing at an estimated CAGR ... new study by Grand View Research, Inc. Introduction of ... devices by the geriatric population, along with increase in ... the major drivers of this market. In addition, presence ...
    (Date:7/29/2014)... July 29, 2014 On Friday, the ... declaring the week of October 12-18, 2014, as "National ... management in improving healthcare outcomes for patients. The resolution ... John Boozman (R-AR), with support by the Case Management ... to honor case management professionals for their contributions to ...
    (Date:7/29/2014)... “Our years of experience with ... to insulate their homes properly simply due to ... heat transfer and conduction,” Clean Crawls says in ... released an article explaining exactly how heat ... bills. , To contact Clean Crawls for their ...
    Breaking Medicine News(10 mins):Health News:Early Hormone Therapy May Be Safe for Women's Hearts 2Health News:Early Hormone Therapy May Be Safe for Women's Hearts 3Health News:Scientists to study hereditary breast cancer to find BRCA1 treatment 2Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 2Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 4Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 5Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 6Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:What’s The Point of Insulation? Clean Crawls Explains The Dangers of Heat Transfer in Recently Released Article 2
    ... men generally have lower prostate specific antigen levels than men ... the PSA test may not be as good at identifying ... 2,800 men with no evidence of prostate cancer. Results showed ... across all age groups and throughout all races. A study ...
    ... is effective in reducing the risk of death following a ... attack // find researchers according to latest research. ,In ... reviparin on the composite outcome of death, heart attack, and ... was reduced from 11 percent of patients in the placebo ...
    ... broiled fish, such as tuna, may lower stroke risk ... adults 65 and older. Study participants answered food-frequency questionnaires ... years. ,Results showed 626 of the participants experienced ... broiled or baked fish one- to four-times per week ...
    ... with a long-acting beta2-agonist (formoterol) can actually provide significant ... high doses of inhaled steroid, say researchers according to ... of various combinations of medicine on asthma symptoms in ... were analyzed. The patients were divided into three treatment ...
    ... over whether hormone replacement therapy is safe and effective ... the pros and cons of this controversial therapy. ... five years. All the women studied were 50 years ... others did not.Results showed women free of menopausal symptoms ...
    ... The use of alternative or complementary therapies have increased ... people using // at least one form of alternative ... biofeedback, yoga, hypnosis, acupuncture, chiropractic care, and high-dose vitamins. ... their own survey taken in 1997 to the National ...
    Cached Medicine News:
    ... order tips. Each box contains 10,000 tips ... in easy-to-open, re-sealable Bulk Packs of 200 ... with a tamper-proof strip which can easily ... Diamond Tips. Bulk Packs are closed using ...
    10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
    10 L, Bulk Recommended for 2, 5, 10 L pipettes....
    ... Theken eDISC is a revolutionary advancement in ... assess and manage their patients. The eDISC's ... the eDISC from 1st and 2nd generation ... loads of the lumbar spine, the eDISC ...
    Medicine Products: